This observation underscores the potential challenges in utilizing HER2-targeted therapies in prostate cancer, as homogeneous expression across metastatic sites may be relevant to the therapeutic activity of agents such as T-DXd. The gene discussed is ERBB2; the disease is prostate cancer.